Photocure ASA Stock price

Equities

PHO

NO0010000045

Pharmaceuticals

Real-time Oslo Bors 09:20:00 2024-03-27 am EDT 5-day change 1st Jan Change
55 NOK -0.90% Intraday chart for Photocure ASA -6.46% -18.40%
Sales 2023 446M 41.14M Sales 2024 * 495M 45.63M Capitalization 1.49B 137M
Net income 2023 - 0 Net income 2024 * - 0 EV / Sales 2023 4.09 x
Net cash position 2023 * 238M 21.99M Net cash position 2024 * 256M 23.6M EV / Sales 2024 * 2.49 x
P/E ratio 2023
6,740 x
P/E ratio 2024 *
1,296 x
Employees 88
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.90%
1 week-6.46%
Current month-1.79%
1 month+2.80%
3 months-17.91%
6 months+4.96%
Current year-18.40%
More quotes
1 week
54.50
Extreme 54.5
58.90
1 month
52.50
Extreme 52.5
66.00
Current year
52.00
Extreme 52
71.90
1 year
40.70
Extreme 40.7
71.90
3 years
40.70
Extreme 40.7
154.50
5 years
40.00
Extreme 40
154.50
10 years
17.70
Extreme 17.7
154.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-10-31
Director of Finance/CFO - 12-08-14
Chief Tech/Sci/R&D Officer - 21-07-31
Members of the board TitleAgeSince
Director/Board Member - 17-04-27
Director/Board Member 51 -
Chairman - -
More insiders
Date Price Change Volume
24-03-27 55 -0.90% 40,039
24-03-26 55.5 -1.60% 56,614
24-03-25 56.4 -1.91% 22,006
24-03-22 57.5 -0.17% 23,592
24-03-21 57.6 -2.04% 66,377

Real-time Oslo Bors, March 27, 2024 at 09:20 am EDT

More quotes
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company's activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
55 NOK
Average target price
86 NOK
Spread / Average Target
+56.36%
Consensus
  1. Stock
  2. Equities
  3. Stock Photocure ASA - Oslo Bors